Atrial fibrillation and peripheral arterial disease define MPN patients with very high risk of thrombosis

Herbreteau, Laura; Couturaud, F.; Hoffmann, Clément; Bressollette, Luc; Pan‐Petesch, Brigitte; Rio, Laetitia; Lippert, Éric; Ianotto, Jean‐Christophe

doi:10.1016/j.thromres.2023.04.021

Cited by 5 publications

(1 citation statement)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, elevated variant allele frequencies of JAK2V617F and neutrophil-to-lymphocyte ratios are associated with notable inflammation, arterial stiffness, and atherosclerosis in MPNs[ 95 - 97 ]. Furthermore, in subjects with atherosclerosis, dyslipidemia is associated with increased concentrations of platelet-derived growth factor and other cytokines which are molecules known to stimulate proliferation of myeloid cells, and peripheral arterial disease, a vascular complication driven by lipid abnormalities and atherogenesis, has been shown along with atrial fibrillation to be a notable predictor of thrombotic and bleeding complications, as well as death in MPNs[ 98 , 99 ]. Thus, the crosstalk between dyslipidemia, inflammation, and oxidative stress may stimulate a process of accelerated atherosclerosis in MPNs and eventually results in higher rates of thrombotic and, in some cases, hemorrhagic complications in these hematological malignancies (Figure 1 )[ 100 ].…”

Section: Molecular Mechanisms Common In Dyslipidemia Mets and Mpnsmentioning

confidence: 99%

Overview of dyslipidemia and metabolic syndrome in myeloproliferative neoplasms

Găman,

Srichawla,

Chen

et al. 2024

World J Clin Oncol

View full text Add to dashboard Cite

Myeloproliferative neoplasms (MPNs) occur due to the abnormal proliferation of one or more terminal myeloid cell lines in peripheral blood. Subjects suffering from MPNs display a high burden of cardiovascular risk factors, and thrombotic events are often the cause of death in this population of patients. Herein, we provide a brief overview of dyslipidemia and metabolic syndrome and their epidemiology in MPNs and examine the common molecular mechanisms between dyslipidemia, metabolic syndrome, and MPNs, with a special focus on cardiovascular risk, atherosclerosis, and thrombotic events. Furthermore, we investigate the impact of dyslipidemia and metabolic syndrome on the occurrence and survival of thrombosis in MPN patients, as well as the management of dyslipidemia in MPNs, and the impact of MPN treatment on serum lipid concentrations, particularly as side/adverse effects reported in the context of clinical trials.

show abstract